FPR1 and pulmonary fibrosis: OBE022, an FPr antagonist in clinical development as a tocolytic (35, 41), and BAY6672, a quinolone-based FPr antagonist shown to attenuate silica-induced lung fibrosis in mice (36), each blocked fibrotic endpoints with effect sizes similar to nintedanib alone.